Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2013 · second_quarter · Q2
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Source: Senate LDA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S. 619; Strategies to Address Antimicrobial Resistance (STAAR) Act.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Strategies to Address Antimicrobial Resistance Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Strategies to Address Antimicrobial Resistance Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S. 619; Strategies to Address Antimicrobial Resistance (STAAR) Act.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2013 · first_quarter · Q1
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2012 · fourth_quarter · Q4
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2012 · third_quarter · Q3
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR); PDUFA
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2012 · second_quarter · Q2
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; and point-of-care diagnostic tests.
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR); PDUFA
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2012 · first_quarter · Q1
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; and point-of-care diagnostic tests.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2011 · fourth_quarter · Q4
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR).
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2011 · third_quarter · Q3
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR).
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2011 · second_quarter · Q2
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; and support for evidence-based decision making.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2011 · first_quarter · Q1
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR).
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · fourth_quarter · Q4
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; and support for evidence-based decision making.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · third_quarter · Q3
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Medical Liability; Antimicrobial resistance research; Infectious diseases product research and development; Regulatory science; Unnecessary regulatory burdens placed on medical research; laboratory developed tests; Comparative effectiveness research; and Support for evidence-based decision making.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · second_quarter · Q2
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Regulatory science; Unnnecessary regulatory burdens placed on medical research; laboratory developed tests; and Support for evidence-based decision making.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advance Research and Development Authority (BARDA), Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administraton and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · first_quarter · Q1
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · fourth_quarter · 4A
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance (STAAR) Act.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · fourth_quarter · 4A
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens places on medical research; Support for evidence-based decision making.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · fourth_quarter · Q4
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquistion Program; and Healthcare Reform.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · third_quarter · Q3
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · second_quarter · Q2
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
Medical liability; Antimicrobial resistance research; infectious diseases product research and development
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · first_quarter · Q1
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisiton Program
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; Antimicrobial resistance research; infectious diseases product research and development
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · fourth_quarter · Q4
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquistion Program
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2008 · fourth_quarter · 4A
Medical liability; Antimicrobial resistance research; infectious diseases product research and development
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquistion Program
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2008 · third_quarter · Q3
Medical liability; Antimicrobial resistance research; infectious diseases product research and development.
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hopsital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2008 · second_quarter · Q2
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
Funding support for the Centers for Diseases Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2008 · first_quarter · Q1
Medical liability; Antimicrobial resistance research; infectious diseases product research and development.
Funding support for the Centers for Diseases Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; immunizations; pandemic influenza, public health security and bioterrorism; global infectious diseases; biomedical research, Ryan White reauthorization; Lyme disease and other infectious diseases issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2007 · year_end · YA
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; immunizations; pandemic influenza, public health security and bioterrorism; global infectious diseases; biomedical research, Ryan White Reauthorization; Lyme disease and other infectious diseases issues.
Medical liability; Antimicrobial resistance research; infectious diseases product research and development.
Funding support for the Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2007 · mid_year · MM
Competitive Acquisition Program Medicare Part D vaccine coverage and formulary issues Reimbursement for outpatient and home-based infusion therapy Physician payment and coding Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage Average Sales Price
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases-related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2006 · year_end · YY
Funding support for the Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases-related issues.
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; immunizations; pandemic influenza, public health security and bioterrorism; global infectious diseases; biomedical research, Ryan White Reauthorization; Lyme disease and other infectious diseases issues.
Competitive Acquisition Program Medicare Part D vaccine coverage and formulary issues Reimbursement for outpatient and home-based infusion therapy Physician payment and coding Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage Average Sales Price
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2005 · year_end · YY
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2005 · mid_year · MM
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2004 · year_end · YY
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2004 · mid_year · MM
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA), U.S. Agency for International Development (USAID), White House Office
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2004 · mid_year · MM
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA), U.S. Agency for International Development (USAID), White House Office
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2003 · year_end · YY
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2003 · mid_year · MM
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2002 · mid_year · MM
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID), White House Office
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2001 · mid_year · MM
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2001 · year_end · YY
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2000 · mid_year · MA
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2000 · year_end · YY
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2000 · mid_year · MM
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2000 · mid_year · RR
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR).
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; and point-of-care diagnostic tests.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; and support for evidence-based decision making.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR).
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; and support for evidence-based decision making.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S. 619; Strategies to Address Antimicrobial Resistance (STAAR) Act.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Depatment of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; Antimicrobial resistance research; infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; Antimicrobial resistance research; infectious diseases product research and development
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Diseases Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquistion Program
Medical liability; Antimicrobial resistance research; infectious diseases product research and development.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Reimbursement for outpatiend infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; Antimicrobial resistance research; infectious diseases product research and development
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; immunizations; pandemic influenza, public health security and bioterrorism; global infectious diseases; biomedical research, Ryan White Reauthorization; Lyme disease and other infectious diseases issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; Antimicrobial resistance research; infectious diseases product research and development
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE